RPRX - NASDAQ

Royalty Pharma plc

RPRX·NASDAQ

$54.97

+1.8%

HealthcareBiotechnology

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$23.64B

EPS2.3300

P/E Ratio23.59

Earnings Date08/05/2026

19.62B

Assets

3Y+17.0%

5Y+22.0%

10Y+87.0%

9.91B

Total Liabilities

26%

3Y+36.0%

5Y+62.0%

10Y+64.0%

9.71B

Total Equity

-6%

3Y+2.0%

5Y-2.0%

10Y+119.0%

Royalty Pharma plc Funding & Solvency Profile

RPRX · NASDAQ

Current Assets

Cash & Cash Equivalents618.70M

Net Receivables883.70M

Inventory0.00

Other Current Assets-902.20M

Total Current Assets619 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets924.63M

Long-Term Investments171.31M

Other Non-Current Assets15.97B

Total Non-Current Assets16 B

Total Assets

19.62B

Financial Health Analysis

Current Ratio

0.97x

Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.

Debt-to-Equity Ratio

1.02x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

-17211000

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

3% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Negative working capital with limited cash reserves requires immediate attention—potential liquidity crisis if not addressed promptly.

Royalty Pharma plc Balance Sheet

RPRX • NASDAQ

Royalty Pharma plc Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	618.7M	929M	477M	1.7B	1.5B	1B	246.2M	1.9B	1.4B	1.7B	1.7B
Short-Term Investments	18.8M	842M	756.7M	717M	1.3B	1.6B	547M	461.8M	0.0	0.0	0.0
Cash & Short-Term Investments	637.5M	1.8B	1.2B	2.4B	2.8B	2.6B	793.2M	2.4B	1.4B	1.7B	1.7B
Net Receivables	883.7M	27M	22.4M	36.6M	68.3M	39.2M	38.8M	198.6M	0.0	0.0	0.0
Accounts Receivables	883.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	27M	22.4M	36.6M	68.3M	39.2M	38.8M	198.6M	0.0	0.0	0.0
Other Current Assets	-902.2M	4.2M	18M	90.5M	6.6M	8.6M	92K	23.9M	1.6B	1.3B	1.3B
Total Current Assets	619M	1.8B	1.3B	2.6B	2.9B	2.7B	832.1M	2.6B	2.9B	3B	3B
NON-CURRENT ASSETS
Goodwill	924.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	15.1B	0.0	0.0	5.7M	28.7M	51.7M	75.6M	0.0	0.0	6.9B
Goodwill & Intangible Assets	924.6M	15.1B	0.0	0.0	5.7M	28.7M	51.7M	75.6M	0.0	0.0	6.9B
Long-Term Investments	171.3M	16.4B	15.1B	14.2B	14.6B	13.3B	11.5B	8.7B	0.0	0.0	0.0
Other Non-Current Assets	16B	-15.1B	6.5M	29.6M	4.1M	10M	88M	19.1M	0.0	0.0	822.3M
Total Non-Current Assets	17.1B	16.4B	15.1B	14.3B	14.6B	13.3B	11.6B	8.8B	8.4B	7.5B	7.8B
Other Assets	1.9B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	19.6B	18.2B	16.4B	16.8B	17.5B	16B	12.4B	11.4B	11.4B	10.5B	10.8B
LIABILITIES
CURRENT LIABILITIES
Total Payables	92.2M	89.2M	98.3M	102.7M	113.6M	137.1M	42.2M	298.7M	0.0	0.0	0.0
Accounts Payable	19.4M	13.4M	15.2M	7.9M	5.6M	10.8M	11.2M	4.5M	0.0	0.0	0.0
Other Payables	72.8M	75.8M	83.2M	94.8M	107.9M	126.4M	31M	294.3M	0.0	0.0	0.0
Accrued Expenses	0.0	98.1M	51.7M	54.2M	57.7M	152.1M	0.0	0.0	0.0	0.0	0.0
Short Term Debt	380M	997.8M	0.0	997.5M	0.0	0.0	282M	281.4M	280.9M	172.7M	184.4M
Other Current Liabilities	164M	68.6M	11.4M	12.4M	0.0	18.6M	9.2M	0.0	102.5M	124.6M	130M
Total Current Liabilities	636.2M	1.3B	161.4M	1.2B	171.3M	307.9M	333.4M	580.2M	383.4M	297.3M	314.4M
NON-CURRENT LIABILITIES
Long Term Debt	8.6B	6.6B	6.1B	6.1B	7.1B	5.8B	6B	6.2B	6.5B	5.7B	5.8B
Other Non-Current Liabilities	682.6M	12.1M	900K	2.5M	0.0	0.0	18.9M	0.0	0.0	0.0	0.0
Total Non-Current Liabilities	9.3B	6.6B	6.1B	6.1B	7.1B	5.8B	6B	6.2B	6.5B	5.7B	5.8B
Capital Lease Obligations	16.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	9.9B	7.9B	6.3B	7.3B	7.3B	6.1B	6.3B	6.8B	6.9B	6B	6.1B
SHAREHOLDERS' EQUITY
Treasury Stock	-2.6M	-2.7M	-2.6M	-2.8M	-2.7M	-2.3M	-4.3M	0.0	0.0	0.0	0.0
Common Stock	106K	108K	108K	107K	106K	102K	3.3B	3.3B	0.0	0.0	0.0
Additional Paid-In Capital	4.1B	4.1B	4B	3.7B	3.5B	2.9B	0.0	0.0	0.0	0.0	0.0
Retained Earnings	2.4B	2.8B	2.5B	2B	2.3B	1.9B	2.8B	1.2B	0.0	0.0	0.0
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	16.5M	34.4M	2.1M	-10.3M	0.0	0.0	0.0
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5B	4.4B	4.7B
Total Stockholders' Equity	6.5B	6.9B	6.5B	5.6B	5.8B	4.8B	6.1B	4.5B	4.5B	4.4B	4.7B
Total Equity	9.7B	10.3B	10.1B	9.5B	10.2B	9.9B	6.1B	4.6B	4.5B	4.4B	4.7B
Minority Interest	3.2B	3.4B	3.6B	3.9B	4.5B	5.1B	35.9M	63.9M	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	19.6B	18.2B	16.4B	16.8B	17.5B	16B	12.4B	11.4B	11.4B	10.5B	10.8B
Total Investments	190.1M	17.2B	15.9B	14.9B	15.9B	14.9B	12B	9.1B	0.0	0.0	0.0
Total Debt	9B	7.6B	6.1B	7.1B	7.1B	5.8B	6.2B	6.5B	6.8B	5.9B	6B
Net Debt	8.3B	6.7B	5.7B	5.4B	5.6B	4.8B	6B	4.6B	5.4B	4.2B	4.3B
Shares Outstanding	434,111,207	434,111,207	434,111,207	434,111,207	434,111,207	434,111,207	434,111,207	434,111,207	434,111,207	434,111,207	434,111,207

SEC Filings

RPRX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 28, 2026	May 22, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 13, 2026	April 13, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 10, 2026	June 04, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 11, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 11, 2026	February 11, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 22, 2025	December 19, 2025	2025	View Filing
8-K 8-K 2025 N/A	December 22, 2025	December 20, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing

Showing 1 to 10 of 113 filings

Related Guides

Blog Categories

Continue your RPRX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.